AbGn-268

Leiolizumab

Therapeutic Area

Product Overview
Inheriting the unique mechanism of action from AbGn-168H, AbGn-268 is subtly designed as a multiple-valence molecule to achieve a better efficacy. From preliminary experimental results, AbGn-268 exhibits not only comparable safety profiles, but also improved potency in eliminating chronic pathogenic T cells. Therefore, a lower dosage to obtain an equal efficacy in clinical is expected.

The preclinical production of AbGn-268 is planned in Q1 of 2019, and Q3 of 2020 is the target for an Investigational New Drug (IND) application filing with the U.S. FDA.

Indication

Inflammation Disease

1

  • PRECLINAICAL

    Preclinical

  • PHASE I

  • PHASE IIA

  • PHASE IIB

  • PHASE III

  • MARKET

Introduction

T cells play a key role in immune system, and are particularly important in the chain of events that are believed to lead to the inflammation and autoimmunity.

Based on current structure of AbGn-168H, a second generation of the therapeutic antibody with multivalent design that leads to improve potency is being under development. So far, in vitro and in vivo studies with this modified antibody have demonstrated a 10-fold increase at least in activity of abolishing activated T cells (killer immune cells that cause inflammation). The company is dedicated to bring forth this potential candidate for pre-clinical studies.